Medicus Pharma Ltd. 8-K

What Happened

• Medicus Pharma Ltd. held its 2026 Annual General and Special Meeting on June 3, 2026 and filed an 8-K reporting the results. Shareholders ratified KPMG LLP as the company’s independent registered public accounting firm for the 2026 fiscal year, elected all nine board nominees to one-year terms, and approved a special resolution authorizing the Board to effect a consolidation of common shares up to a maximum ratio of 50 pre-consolidation shares for one post-consolidation share.

Key Details

• Auditor ratification (Proposal 1): For 28,308,860; Withhold 756,378; Broker non-votes 0.
• Director elections (Proposal 2): All nine nominees elected; individual "For" votes ranged roughly 15.07M–15.20M with withholds ~345k–467k; broker non-votes 13,529,765. Directors re-elected include William L. Ashton, Dr. Raza Bokhari, Robert J. Ciaruffoli, Barry Fishman, Dr. Larry Kaiser, Patrick Mahaffy, Dr. Sara R. May, Hon. Cathy McMorris Rodgers, and Ajay Raju.
• Share consolidation authorization (Proposal 3): Approved with For 26,729,776; Against 2,335,461; Broker non-votes 1. Approval permits the Board to choose a consolidation ratio up to 50:1 if it deems it necessary or desirable (e.g., to meet exchange or regulatory requirements).

Why It Matters

• The votes preserve management and audit continuity (same auditors and the full slate of directors re-elected), which can reduce near-term governance uncertainty.
• The approved authorization to consolidate shares (up to 50-for-1) gives the Board a tool to change the company’s outstanding share count and per-share metrics if needed — a move often used to meet listing standards or adjust the quoted share price. This is an enabling measure; any actual consolidation would require Board action and be disclosed separately.